IMNM
What one share of Immunome holds
Pharmaceutical Preparations
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients.
Immunome’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$2.49 |
| Capex (buildings and equipment) | $0.10 |
| Free cash flow | −$2.14 |
| Cash and investments | $1.92 |
| Book value | $4.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$9.55 | $0.21 | −$8.99 | — | −$32.41 |
| 2020 | — | −$5.26 | $0.17 | −$3.75 | — | — |
| 2021 | — | −$2.14 | $0.01 | −$1.59 | — | $3.98 |
| 2022 | — | −$3.09 | $0.02 | −$2.39 | — | $1.37 |
| 2023 | $0.71 | −$5.38 | $0.04 | −$0.42 | — | — |
| 2024 | $0.15 | −$5.00 | $0.12 | −$2.01 | — | $2.81 |
| 2025 | $0.08 | −$2.43 | $0.11 | −$2.30 | — | $5.61 |